First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

Br J Cancer · 2004 · PMC2395329 · PMID 14710200

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Interpretation of the advanced disease data The letrozole experience, by virtue of the consistent findings and highly significant effects on the TTP and response rate, provided the best evidence for the advantage of first-line AI treatment.

also in 132,142 other papers

a clear trendno p-value reported

Whereas women on letrozole had a clear trend towards improved survival during the first 2 years, this survival benefit was ‘lost’ after further follow-up (median survival 34 months with letrozole vs 30 months for tamoxifen).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.